CN100348229C - Capsule prepn for treating laryngopharyngitis and tonsillitis and its prepn process - Google Patents
Capsule prepn for treating laryngopharyngitis and tonsillitis and its prepn process Download PDFInfo
- Publication number
- CN100348229C CN100348229C CNB2005102005674A CN200510200567A CN100348229C CN 100348229 C CN100348229 C CN 100348229C CN B2005102005674 A CNB2005102005674 A CN B2005102005674A CN 200510200567 A CN200510200567 A CN 200510200567A CN 100348229 C CN100348229 C CN 100348229C
- Authority
- CN
- China
- Prior art keywords
- herba andrographis
- herba
- starch
- pvp
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a capsule for curing pharyngolaryngitis and tonsillitis, and a preparation method thereof. The capsule is prepared from oldenlandia diffusa, common andrographis herb, narrowleaf screwtree root and auxiliary materials; the containing substance is dirty green particles or powder having light smell and bitter taste; the present invention is not only used for curing acute pharyngolaryngitis and tonsillitis, but also has good curative effect on chronic pharyngolaryngitis, polyp of vocal cords and nodulation of vocal cords; the capsule has the advantages of no toxic or side effect, no recurrence after curing, short disintegration time, ideal dissolution and absorption, and stable quality.
Description
Technical field: the present invention relates to a kind of treatment pharyngolaryngitis, tonsillitic capsule preparations and preparation method, belong to technical field of Chinese medicine.
Background technology: acute and chronic pharyngitis, tonsillitis, polyp of vocal cord, vocal nodule are otorhinolaryngologic common diseases, and sickness rate is higher.Often adopt Drug therapy such as antibiotic, hormone, spray, compound Chinese medicinal preparation at present clinically or adopt laser, operative treatment such as freezing.These pharmaceutical preparatioies can be played certain therapeutic effect to acute pharyngolaryngitis, tonsillitis, and to chronic pharyngolaryngitis, and polyp of vocal cord, vocal nodule unsatisfactory curative effect, and also have certain toxic and side effects.Though laser, operative treatment therapeutic effect such as freezing are better, recurrence easily, relapse rate is higher.Larynx oxazepam of the prior art has the effect of heat-clearing and toxic substances removing, dispersing swelling and dissipating binds, not only cures mainly acute pharyngolaryngitis, tonsillitis, and better to the curative effect of chronic pharyngolaryngitis and polyp of vocal cord, vocal nodule, and has no side effect, and cures the back and is difficult for recurrence.Also can be used for incidence cancerous protuberance caused various inflammation and cancerous protuberance auxiliary treatment during radiotherapy simultaneously.But the dosage form of larynx oxazepam is coated tablet or Film coated tablets, and its disintegration time is long, stripping and absorption is not ideal enough and do not have the assay project of Main Ingredients and Appearance in its quality standard, and quality is difficult for effectively control.
Summary of the invention: the objective of the invention is to: a kind of treatment pharyngolaryngitis, tonsillitic capsule preparations and preparation method are provided, and its disintegration time weak point, stripping and absorption ideal and steady quality are to solve the problem that prior art exists.
The present invention is achieved in that according to listed as parts by weight, and it adds adjuvant for 300～600 parts by 600～900 parts of Herba Hedyotidis Diffusaes, 400～800 parts of Herba Andrographis and Radix Helicteris and is prepared from, and content is dirty green particles or powder, feeble QI, bitter in the mouth; Say accurately, calculate according to weight that it adds adjuvant by Herba Hedyotidis Diffusae 833g, Herba Andrographis 667g and Radix Helicteris 500g and is prepared from, described adjuvant is starch, PVP, microcrystalline Cellulose.
The present invention treats pharyngolaryngitis, tonsillitic capsule preparations is preparation like this: weighting raw materials material Herba Hedyotidis Diffusae, Herba Andrographis and Radix Helicteris, get part Herba Andrographis, and be ground into fine powder, standby; Residue Herba Andrographis and Herba Hedyotidis Diffusae, Radix Helicteris decoct with water 1～3 time, each 0.5～2 hour, add 8～12 times of amounts that water is crude drug the 1st time, the 2nd time is 5～9 times of amounts of crude drug, and collecting decoction filters, filtrate is condensed into thick paste, and drying adds above-mentioned Herba Andrographis fine powder and appropriate amount of auxiliary materials, mixing, make wetting agent system soft material with 70～90% ethanol, 20～40 order rustless steel sieve series granules, encapsulated 70 ℃～80 ℃ dry down backs, make 1000, promptly.
The best preparation method that the present invention treats pharyngolaryngitis, tonsillitic capsule preparations is: weighting raw materials material Herba Hedyotidis Diffusae 833g, Herba Andrographis 667g and Radix Helicteris 500g, get Herba Andrographis 100g, and be ground into fine powder, standby; Residue Herba Andrographis and Herba Hedyotidis Diffusae, Radix Helicteris decoct with water 2 times, each 1 hour, adding water for the 1st time is 10 times of amounts of crude drug, the 2nd time is 7 times of amounts of crude drug, and collecting decoction filters, filtrate is condensed into thick paste, drying adds above-mentioned Herba Andrographis fine powder, mixing, again by adding medicine: starch: PVP: microcrystalline Cellulose=4: 1: 1: 1 part by weight, add adjuvant, mixing is made wetting agent system soft material with 85% ethanol, 30 order rustless steel sieve series granules, encapsulated 70 ℃～80 ℃ dry down backs, make 1000, promptly.
Herba Hedyotidis Diffusae is the dry herb of Maguireothamnus speciosus Herba Hedyotidis Diffusae in the side.Main product Guangdong Province, gather autumn, and " Zhejiang Province's Chinese medicine processing version in 1994 " recorded, and has heat-clearing and toxic substances removing, and the reducing swelling and alleviating pain function cures mainly appendicitis, tracheitis, urinary tract infection, venom, tumor, discharging fresh blood stool.Herba Andrographis is the dry aerial parts of acanthaceous plant Herba Andrographis, gathers during leafiness at the beginning of the autumn." Chinese Pharmacopoeia 2000 version one one " records, has heat-clearing and toxic substances removing, removing heat from blood, and the detumescence function cures mainly cold, fever, laryngopharynx swelling and pain, aphtha of the mouth and tongue, pertussis chronic cough, dysentery, the puckery pain of pyretic stranguria, carbuncle skin infection, venom.Radix Helicteris is the dry root of Sterculiaceae plant Radix Helicteris, and summer, autumn gather, and " Chinese Pharmacopoeia 1977 version one one " records, have effects for removing toxic heat, cures mainly the flu hyperpyrexia, tonsillitis, pharyngolaryngitis, parotitis, skin eczema.We's medication refine, compatibility is reasonable, the match effect of mutual aid heat-clearing and toxic substances removing, removing obstruction for relieving pain of all medicines, cure mainly acute and chronic pharyngolaryngitis, acute tonsillitis, polyp of vocal cord, vocal nodule, and can be used for the auxiliary treatment of incidence cancerous protuberance caused various inflammation and cancerous protuberance during radiotherapy.
Compare with the larynx oxazepam of prior art, the present invention has disintegration time weak point, stripping and absorption ideal, stay-in-grade advantage.The applicant finds in experiment, and the method that this product adopts water to carry makes, and extractum contains hydrophilic compositions such as phlegmatic temperament, polysaccharide, inorganic salt, easily absorbs airborne moisture, just capsule deliquescing, caking even go mouldy, thus influence the quality and the curative effect of medicine.Add the poorly water-soluble of the effective ingredient andrographolide of Herba Andrographis, disintegration rate has influence on dissolution, influences product quality and clinical efficacy greatly.
Technical study of the present invention:
1, Research on Process:
1.1 prescription, prescription foundation and technology
1.1.1 prescription: Herba Hedyotidis Diffusae 833g, Herba Andrographis 667g, Radix Helicteris 500g
1.1.2 prescription foundation: this prescription is according to " the 20th in the Sanitation Ministry medicine standard Chinese traditional patent formulation preparation " WS
3-B-4013-98 larynx oxazepam quality standard.
1.1.3 technology:
1.1.3.1 method for making: above three flavors, get Herba Andrographis 100g, be ground into fine powder; Residue Herba Andrographis decocts with water secondary with white Herba Hedyotidis Diffusae, Radix Helicteris, each 1 hour, adds 10 times of amounts that water is crude drug for the first time, be 7 times of amounts for the second time, collecting decoction filters, filtrate is condensed into thick paste, drying adds above fine powder and suitable adjuvant, makes granule, dry, incapsulate, make 1000, promptly.
1.1.3.2 technical study: this product technical study is basic with reference to " the 20th in the Sanitation Ministry medicine standard Chinese traditional patent formulation preparation " WS
3[method for making] of-B-4013-98 larynx oxazepam.
1.1.3.2.1 determining of decoction amount of water: stipulate decocting amount of water in former [method for making] item, consider that amount of water may influence the dried cream volume production of being extracted is living, therefore test and determine the decoction amount of water by the rate of extract.The results are shown in following table:
Different amount of water decoct the rate of extract are influenced
| Sequence number | 1 | 2 | 3 | 4 | |
| For the first time | 8 times | 9 times | 10 times | 12 times | |
| Amount of water | For the second time | 6 times | 6 times | 7 times | 7 times |
| Dried cream yield(％) | 5.21 | 5.52 | 7.58 | 7.62 | |
By table as seen, along with the increase of amount of water, dried cream yield increases; But after increasing to 10 times, 7 times, dried cream yield has not had obvious increase, and therefore determining to decoct amount of water is 10 times for the first time, 7 times for the second time.
1.1.3.2.2 determining of loading amount: according to the punching Nelumbo nucifera Gaertn. Powder dosage that dried cream yield (about 7.5%) and prescription are stipulated, recipe quantity both with about 250g (1000).Consider the different places of production of Chinese medicine and collection season, extraction ratio can change to some extent, so need to adjust with appropriate amount of auxiliary materials, every loading amount is decided to be 0.3g.
1.1.3.2.3 adjuvant determines in the preparation
1.1.3.2.3.1 hygroscopicity experiment
Select adjuvants commonly used such as starch, lactose for use, design 6 different prescriptions, see the following form.Amount by regulation in the table takes by weighing extract powder and adjuvant, and mix homogeneously is crossed 80 mesh sieves, puts constant weight 48h in the phosphorus pentoxide desiccator.
Composition (g) prescription
1 2 3 4 5 6
Extract powder 20 20 20 20 20 20
Starch 5
Lactose 5
pvp 5
Starch+lactose (1: 1) 5
Starch+pvp (1: 1) 5
The glass exsiccator that the bottom is filled the Nacl supersaturated solution is put into constant incubator, and in 25 ℃ of constant temperature, making the relative humidity in the exsiccator is 75%.Put into the medicated powder of thick 2mm in the weighing botle bottom of constant weight, precision is weighed (the weighing bottle cap is opened, 25 ℃ of constant temperature) in the rearmounted above-mentioned glass exsiccator, respectively at 12h, 24h, 48h, 78h) weigh, be calculated as follows the moisture absorption percentage rate, the results are shown in Table.
Different prescription medicated powder moisture absorption percentage rate %
| Prescription | Time | |||
| 12h | 24h | 48h | 78h | |
| 1 2 3 4 5 6 | 11.1 10.3 7.2 9.8 9.1 8.3 | 15.6 14.7 11.1 13.6 13.2 12.4 | 18.3 17.6 14.5 15.8 15.5 15.3 | 19.2 19.1 15.6 18.7 18.2 17.8 |
As seen from the above table, select medicine for use: starch: PVP: microcrystalline Cellulose=4: 1: 1: 1 ratio can reduce the product hygroscopicity.
1.1.3.2.3.2 the mensuration of disintegration time
Different auxiliary material reaches and the contrast that contrasts tablet the influence of capsule disintegrate
| Group | Medicine: starch: PVP 4: 1: 1 | Medicine: starch: PVP: microcrystalline Cellulose 4: 1: 1: 1 | The contrast tablet |
| Disintegration time | 32 minutes | 10 minutes | 43 minutes |
As seen from the above table, only use starch, two kinds of adjuvants of PVP, the capsule disintegration time is longer, and for improving disintegration rate, we add microcrystalline Cellulose, and its consumption is investigated.
The microcrystalline Cellulose consumption is screened
| Group | Medicine: starch: PVP: microcrystalline Cellulose | Disintegration time (min) |
| 1 2 3 4 5 6 | 4∶1∶1∶0.5 4∶1∶1∶1 4∶1∶1∶1.5 4∶1∶1∶2 4∶1∶1∶2.5 4∶1∶1∶3 | 12 10 11 13 14 13 |
As seen from the above table, Zui You supplementary product consumption is a medicine: starch: PVP: microcrystalline Cellulose=4: 1: 1: 1.
1.1.3.2.3 determining of wetting agent:
1.1.3.2.3.1 the influence of different wetting agent: relatively adopt purified water, the influence of ethanol to granulating from the complexity and the particulate elasticity of the operation of granulating to granulating.
The influence of different wetting agent to granulating
| Wetting agent | Operation | Granule |
| Purified water | Difficulty | Tightly |
| Ethanol | Easily | Pine |
Because the stickiness of cream powder own is stronger in the material, adopt purified water to do to glue screen cloth when wetting agent is granulated, cause operating difficulties, made granule is too tight, is unfavorable for the stripping of medicine, therefore adopts alcohol granulation.
1.1.3.2.3.2 the variable concentrations wetting agent is to the influence of granule and loading amount: adopt 75%, 85%, 95% ethanol to make wetting agent respectively, concentration of alcohol difference as a result, make granulation mass density difference: concentration of alcohol is high more, and the gained granule is more loose, influences the capsule loading amount.
1.2.2.2 batching:
| Concentration of alcohol | Granulation mass density (g/ml) | Capsules loading amount (g) | ||
| 0# | 1# | 2# | ||
| 75 ％ | 0.67 | 0.502 | 0.368 | 0.268 |
| 85 ％ | 0.55 | 0.412 | 0.301 | 0.221 |
| 95 ％ | 0.51 | 0.382 | 0.280 | 0.204 |
Select for use 85%L alcohol to make wetting agent and granulate, it is comparatively suitable to adopt the 1# capsule to fill.
1.2, pilot process
1.2.1 prescription (10000): Herba Hedyotidis Diffusae 8.33kg, Herba Andrographis 6.67kg, Radix Helicteris 5.00kg.
1.2.2 method for making:
1.2.2.1 Chinese medicine extraction: above samadhi, get Herba Andrographis 1.00kg, it is standby to be ground into fine powder; Residue Herba Andrographis decocts with water secondary with white Herba Hedyotidis Diffusae, Radix Helicteris, and each 1 hour, add 10 times of amounts that water is crude drug for the first time, be 7 times of amounts for the second time, collecting decoction filters, and filtrate is condensed into thick paste, drying, dried cream powder is broken standby.
Dried cream powderExtracted amount
Punching Nelumbo nucifera Gaertn. Powder 1.00kg
Starch is an amount of
Make 10000
1.2.2.3 mixing, granulation, dry, packing: with dried cream powder, punching Nelumbo nucifera Gaertn. Powder and auxiliary materials and mixing, make wetting agent system soft material with 85% ethanol, 30 order rustless steel sieve series granules, encapsulated after 70 ℃～80 ℃ dryings, make 10000, adorn 0.3g for every; Aluminium-plastic bubble plate packing, 12 of every plates; Per 2 plates are adorned capsule with complex pocket sealing back; Every case is adorned 100 boxes.
1.2.3 the three batches of pilot scale data and product inspection data:
Three batches of pilot scale product inspection data
Medicine stability research:
1. general introduction:, this product has been carried out accelerated test and long term test according to Chinese Pharmacopoeia version appendix in 2000 medicine stability test guideline.
2. sample situation:
2.1 sample title: this product larynx oxazepan capsule
2.2 sample source: pilot scale chamber
2.3 sample requirement and lot number: three batches of pilot products, actual commercially available back are that plastic-aluminum bubble-cap, aluminium foil bag add carton package; Sample lot number: 031001,031002,031003
3. investigation project: character, moisture, disintegration, microbial limit, content.
4. test method and result:
4.1 accelerated test method and result: with three batches of pilot products, behind the commercially available back (plastic-aluminum bubble-cap, aluminium foil bag add carton package), place the close drying device (humidity is 75% ± 5%) that saturated sodium-chloride is housed, put in 40 ℃ ± 2 ℃ the Constant Temp. Oven.Take a sample respectively once the 0th, 1,2,3 and 6 the end of month at duration of test, detects by the investigation project of afore mentioned rules, the results are shown in following table.
Larynx oxazepan capsule accelerated test result
| Store | Store | The investigation project | |||||
| Lot number | Time | Moisture | Disintegration | Microorganism | Content mg | ||
| Condition | (moon) | Character | ％ | (min) | Limit test | Dehydrorographolide | |
| Play storage 031,001 2003 on October 25, | 10℃±2℃ 75 ％±5 ％ | 0 1 2 3 6 | For dirty greenPowder For dirty greenPowder For dirty greenPowder For dirty greenPowder For dirty greenPowder | 5.96 6.82 7.47 7.72 8.15 | 10 10 10 10 10 | Up to specification up to specification | 1.976 1.952 1.907 1.917 1.916 |
| Play storage 031,002 2003 on October 25, | 10℃±2℃ 75 ％±5 ％ | 0 1 2 3 6 | For dirty greenPowder For dirty greenPowder For dirty greenPowder For dirty greenPowder For dirty greenPowder | 5.59 6.97 7.54 7.81 8.02 | 12 10 10 12 10 | Up to specification up to specification | 1.962 1.947 1.951 1.933 1.919 |
| Play storage 031,003 2003 positive October 25 | 10℃±2℃ 75 ％±5 ％ | 0 1 2 3 6 | For dirty greenPowder For dirty greenPowder For dirty greenPowder For dirty greenPowder For dirty greenPowder | 5.98 7.20 7.65 7.93 8.12 | 12 10 10 10 10 | Up to specification up to specification | 2.164 2.167 2.148 2.129 2.134 |
4.2 long term test method and result: with three batches of pilot products, behind the commercially available back (plastic-aluminum bubble-cap, aluminium foil bag add carton package), place the close drying device that saturated sodium nitrite is housed. (humidity is 60% ± 10%), keeping temperature is 25 ℃ ± 2 ℃, place and also took a sample respectively once the 0th, 3,6,9,12,18,24 and 36 the end of month respectively in 36 months, investigation project by afore mentioned rules detects, and investigates its mass change, the results are shown in following table.
Larynx oxazepan capsule long-term test results
| Store | Store | The investigation project | |||||
| Lot number | Time | Moisture | Disintegration | Microorganism | Content mg | ||
| Condition | (moon) | Character | ％ | (min) | Limit test | Dehydrorographolide | |
| Play storage 031,001 2003 on October 25, | 25℃±2℃ 60 ％± 10％ | 0 3 6 | For dirty greenPowder For dirty greenPowder For dirty greenPowder | 5.96 6.32 6.95 | 10 10 10 | Up to specification up to specification | 1.976 1.947 1.961 |
| Play storage 031,002 2003 on October 25, | 25℃±2℃ 50 ％±10 ％ | 0 3 6 | For dirty greenPowder For dirty greenPowder For dirty greenPowder | 5.59 6.21 6.62 | 12 12 10 | Up to specification up to specification | 1.962 1.967 1.959 |
| Play storage 031,003 2003 on October 25, | 25℃±2℃ 60 ％±10 ％ | 0 3 6 | For dirty greenPowder For dirty greenPowder For dirty greenPowder | 5.98 6.33 6.72 | 12 10 10 | Up to specification up to specification | 2.164 2.159 2.174 |
5. conclusion: above-mentioned every stability test result shows, larynx oxazepan capsule quickens and long term test 6 months, and significant change does not take place its every index, steady quality, and this product quality in 2 year effect duration can keep stable.
6. documents and materials: the larynx oxazepam that Yi Hetang drugmaker in Guangdong produces, authentication code is the accurate word Z44023048 of traditional Chinese medicines, the effect duration of formulating this product is 2 years.
7. the selection of immediate packaging materials: according to this product characteristics, we select good sealing performance aluminium-plastic bubble plate packing form for use, add compound membrane bag encapsulation, prove that through 6 months accelerated tests this kind packing can guarantee the steady quality of product.Immediate packaging materials aluminium foil and PVC solid medicine are all carried out national Bureau of Drugs Supervision's drug packing material standard (trying) with hard sheet, and all come to have by oneself the enterprise of " drug packing material and container registration certificate ".
Study of pharmacy summary: in sum, the larynx oxazepan capsule of this product, every indexs such as its disintegrate, loading amount, assay are qualified, and steady quality can carry out technical scale production, and its manufactured goods quality meets and reports quality standard.The methodology result of the test of dehydrorographolide HPLC assay shows, this method linear relationship is good, r can reach 0.99994 (n=5), in sample size is 0.1051～1.051ug scope, with chromatographic peak area A is abscissa, concentration C (ug/ml) is for vertical coordinate returns, and linear equation is C=0.3960+5.4840 * 10
-6A, its average average recovery is 101.39% (n=5), and RSD is 1.59%, and stability of solution is good.According to reporting quality standard, test agent in three batches of this product to be measured, every detection data all meet the regulation that originally reports standard.
The capsule of this product and the street drug larynx oxazepam of prior art are carried out the comparison of disintegration, dehydrorographolide content, its result such as following table.
| Disintegration min | Dehydrorographolide content | |
| The larynx oxazepam | 43 | 0.63mg/ sheet |
| This product larynx oxazepan capsule | 10～12 | 1.96～2.16mg/ grain |
As seen from the above table, this capsule quality obviously is better than tablet.
The specific embodiment:
Embodiments of the invention 1: weighting raw materials material Herba Hedyotidis Diffusae 833g, Herba Andrographis 667g and Radix Helicteris 500g, get Herba Andrographis 100g, be ground into fine powder, standby; Residue Herba Andrographis and Herba Hedyotidis Diffusae, Radix Helicteris decoct with water 2 times, each 1 hour, adding water for the 1st time is 10 times of amounts of crude drug, the 2nd time is 7 times of amounts of crude drug, collecting decoction, filter, filtrate is condensed into thick paste, drying, add above-mentioned Herba Andrographis fine powder, and according to medicine: starch: PVP: microcrystalline Cellulose=4: 1: 1: 1 part by weight, add starch, PVP and microcrystalline Cellulose mixing, make wetting agent system soft material with 85% ethanol, 30 order rustless steel sieve series granules, encapsulated 70 ℃～80 ℃ dry down backs, make 10000, promptly.Every dress 0.3g (being equivalent to crude drug 2g), aluminium-plastic bubble plate packing, 12 of every plates; Per 2 plates are adorned capsule with complex pocket sealing back; Every case is adorned 100 boxes.This capsule content is dirty green particles or powder, feeble QI, bitter in the mouth.This product is oral, one time 4,3 times on the one.When inflammation that during being used for radiotherapy, is occurred and cancerous protuberance auxiliary treatment: first day 8 first, 6 for the second time, 4 for the third time, later one time 5,3 times on the one, 10 days is a course of treatment.
Embodiments of the invention 2: weighting raw materials material Herba Hedyotidis Diffusae 600g, Herba Andrographis 400g part and Radix Helicteris 300g, get Herba Andrographis 50g, be ground into fine powder, standby; Residue Herba Andrographis and Herba Hedyotidis Diffusae, Radix Helicteris decoct with water 1 time, each 2 hours, adding water for the 1st time is 8 times of amounts of crude drug, decocting liquid filters, filtrate is condensed into thick paste, dry, add above-mentioned Herba Andrographis fine powder, and according to medicine: starch: PVP: microcrystalline Cellulose=4: 1: 1: 1 part by weight, add starch, PVP and microcrystalline Cellulose mixing, make wetting agent system soft material with 70% ethanol, 20 order rustless steel sieve series granules, encapsulated 70 ℃～80 ℃ dry down backs, make 10000, promptly.
Embodiments of the invention 3: weighting raw materials material Herba Hedyotidis Diffusae 900g, Herba Andrographis 800g and Radix Helicteris 600g, get 150g Herba Andrographis, be ground into fine powder, standby; Residue Herba Andrographis and Herba Hedyotidis Diffusae, Radix Helicteris decocts with water 3 times, each 0.5 hour, adding water for the 1st time is 12 times of amounts of crude drug, the 2nd time is 9 times of amounts of crude drug, the 2nd time is 5 times of amounts of crude drug, and collecting decoction filters, filtrate is condensed into thick paste, drying adds above-mentioned Herba Andrographis fine powder, and according to medicine: starch: PVP: microcrystalline Cellulose=4: 1: 1: 1 part by weight, add starch, PVP and microcrystalline Cellulose mixing, make wetting agent system soft material with 90% ethanol, 40 order rustless steel sieve series granules, encapsulated 70 ℃～80 ℃ dry down backs, make 10000, promptly.
Embodiments of the invention 4: weighting raw materials material Herba Hedyotidis Diffusae 700g, Herba Andrographis 600g and Radix Helicteris 400g, get 100g Herba Andrographis, be ground into fine powder, standby; Residue Herba Andrographis and Herba Hedyotidis Diffusae, Radix Helicteris decocts with water 2 times, 1.5 hours for the first time, 1 hour for the second time, adding water for the 1st time is 12 times of amounts of crude drug, the 2nd time is 8 times of amounts of crude drug, and collecting decoction filters, filtrate is condensed into thick paste, drying adds above-mentioned Herba Andrographis fine powder, and according to medicine: starch: PVP: microcrystalline Cellulose=4: 1: 1: 1 part by weight, add starch, PVP and microcrystalline Cellulose mixing, make wetting agent system soft material with 80% ethanol, 30 order rustless steel sieve series granules, encapsulated 70 ℃～80 ℃ dry down backs, make 10000, promptly.
Claims (4)
1. treat pharyngolaryngitis, tonsillitic capsule preparations for one kind, it is characterized in that: according to listed as parts by weight, it adds adjuvant for 300～600 parts by 600～900 parts of Herba Hedyotidis Diffusaes, 400～800 parts of Herba Andrographis and Radix Helicteris and is prepared from, and used adjuvant is starch, PVP and microcrystalline Cellulose, by medicine: starch: PVP: microcrystalline Cellulose=4: 1: 1: 1 part by weight adds; The content that obtains is dirty green particles or powder, feeble QI, bitter in the mouth.
2. according to the described treatment pharyngolaryngitis of claim 1, tonsillitic capsule preparations, it is characterized in that: calculate according to weight, it adds adjuvant by Herba Hedyotidis Diffusae 833g, Herba Andrographis 667g and Radix Helicteris 500g: by medicine: starch: PVP: microcrystalline Cellulose=4: 1: 1: 1 part by weight adding is prepared from.
3. treat the preparation method of pharyngolaryngitis, tonsillitic capsule preparations as claimed in claim 1 or 2, it is characterized in that: weighting raw materials material Herba Hedyotidis Diffusae, Herba Andrographis and Radix Helicteris, get part Herba Andrographis, be ground into fine powder, standby; Residue Herba Andrographis and Herba Hedyotidis Diffusae, Radix Helicteris decoct with water 1～3 time, each 0.5～2 hour, add 8～12 times of amounts that water is crude drug the 1st time, the 2nd time is 5～9 times of amounts of crude drug, and collecting decoction filters, filtrate is condensed into thick paste, and drying adds above-mentioned Herba Andrographis fine powder and appropriate amount of auxiliary materials, mixing, make wetting agent system soft material with 70～90% ethanol, 20～40 order rustless steel sieve series granules, encapsulated 70 ℃～80 ℃ dry down backs, make 1000, promptly.
4. according to the preparation method of the described treatment pharyngolaryngitis of claim 3, tonsillitic capsule preparations, it is characterized in that: weighting raw materials material Herba Hedyotidis Diffusae 833g, Herba Andrographis 667g and Radix Helicteris 500g, get Herba Andrographis 100g, be ground into fine powder, standby; Residue Herba Andrographis and Herba Hedyotidis Diffusae, Radix Helicteris decoct with water 2 times, each 1 hour, adding water for the 1st time is 10 times of amounts of crude drug, the 2nd time is 7 times of amounts of crude drug, collecting decoction filters, and filtrate is condensed into thick paste, dry, add above-mentioned Herba Andrographis fine powder, mixing is pressed medicine: starch: PVP: microcrystalline Cellulose=4: 1: 1: 1 part by weight again, add adjuvant: starch, PVP and microcrystalline Cellulose mixing, make wetting agent system soft material with 85% ethanol, 30 order rustless steel sieve series granules, encapsulated 70 ℃～80 ℃ dry down backs, make 1000, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005102005674A CN100348229C (en) | 2005-09-26 | 2005-09-26 | Capsule prepn for treating laryngopharyngitis and tonsillitis and its prepn process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005102005674A CN100348229C (en) | 2005-09-26 | 2005-09-26 | Capsule prepn for treating laryngopharyngitis and tonsillitis and its prepn process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1739666A CN1739666A (en) | 2006-03-01 |
| CN100348229C true CN100348229C (en) | 2007-11-14 |
Family
ID=36092291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005102005674A Active CN100348229C (en) | 2005-09-26 | 2005-09-26 | Capsule prepn for treating laryngopharyngitis and tonsillitis and its prepn process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100348229C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101966245B (en) * | 2010-10-13 | 2011-11-30 | 郑州后羿制药有限公司 | Compound injection for curing viral diseases in livestock and poultry and preparation method thereof |
| CN102973692A (en) * | 2012-12-20 | 2013-03-20 | 广西健丰药业有限公司 | Houshuning dispersible tablet and preparation method of same |
| CN108619386A (en) * | 2018-05-18 | 2018-10-09 | 杜美丽 | A kind of antitumor Chinese and Traditional Chinese Herb targeted therapies |
| CN108743827B (en) * | 2018-07-24 | 2021-08-31 | 李谊 | Traditional Chinese medicine for treating acute pharyngolaryngitis and preparation method thereof |
| RU2715456C1 (en) * | 2019-03-11 | 2020-02-28 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ЮУГМУ Минздрава России) | Method for prevention of antimicrobial protection disorders in patients operated on for curvature of nasal septum using ultrasonic cavitation and photochromotherapy |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1342456A (en) * | 2001-10-09 | 2002-04-03 | 陈立民 | Process for preparing medicine to prevent and cure diabetes, hyperlipomia and obesity |
-
2005
- 2005-09-26 CN CNB2005102005674A patent/CN100348229C/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1342456A (en) * | 2001-10-09 | 2002-04-03 | 陈立民 | Process for preparing medicine to prevent and cure diabetes, hyperlipomia and obesity |
Non-Patent Citations (1)
| Title |
|---|
| 中华人民共和国卫生部药品标准中药成方制剂第20册 Z20.341 1998 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1739666A (en) | 2006-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2327052T3 (en) | BOTANICAL BASED DRUG FOR THE TREATMENT OF HEPATITIS C. | |
| GB2428974A (en) | Botanical drug or dietary supplement | |
| CN111358839B (en) | Formula granules of polygonum capitatum and preparation method thereof | |
| CN100348229C (en) | Capsule prepn for treating laryngopharyngitis and tonsillitis and its prepn process | |
| CN102614281B (en) | Chinese medicinal composition for improving anoxia endurance and preparation method and application thereof | |
| CN100358493C (en) | Chinese medica preparation for curing hyperplasia of mammary glands and preparation method | |
| CN102266452A (en) | Chinese medicinal composition for enhancing anoxia endurance and preparation method and application thereof | |
| CN101940696B (en) | Method for preparing Chinese medicinal compound Zengshengping | |
| CN102048967A (en) | Inflammation-diminishing and heat-clearing composition and preparation method thereof | |
| CN1943734B (en) | A Chinese traditional medicine for clearing away heat and toxic material | |
| CN100358492C (en) | Preparation of Chinese traditional medicine for curing headache and preparation method | |
| CN111714539B (en) | Liver-protecting composition and preparation method and application thereof | |
| CN103181966A (en) | Heat-clearing acne oral preparation and preparation method thereof | |
| CN106511277A (en) | Polaprezinc granule and preparation method thereof | |
| CN102406897B (en) | Xingnaojing solid medicinal composition and preparation method thereof | |
| CN106729422B (en) | Pulse-activating turmeric powder traditional Chinese medicine composition for assisting tumor radiotherapy and application thereof | |
| KR101452394B1 (en) | Use of amorphophallus rivieri durieu and extract thereof in the manufacture of a medicament for treating acute, chronic bronchitis | |
| CN115944704B (en) | Application of Dachaihu decoction combined with sorafenib in preparation of anti-liver cancer drugs | |
| CN1060663C (en) | Compound Tibet capillary artemisia patent medicine | |
| CN101700323B (en) | Pharmaceutical composition for preventing and treating liver cancer | |
| CN108066397A (en) | Pharmaceutical composition | |
| CN107496485A (en) | The beneficial liver effect of pilose gerbera herb and application technology | |
| CN107898942B (en) | Cold clearing capsule and preparation method thereof | |
| CN1839909A (en) | Aizoon stonecrop granule and its preparation process | |
| CN105288107A (en) | Compound hippophae rhamnoides composition for clearing heat from throat and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |